The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer
Theodora A Constantin1, Anabel Varela-Carver1, Kyle K Greenland1
1Imperial Centre for Translational and Experimental Medicine, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.
Background:
Current strategies to inhibit androgen receptor (AR) are circumvented in castration-resistant prostate cancer (CRPC). Cyclin-dependent kinase 7 (CDK7) promotes AR signalling, in addition to established roles in cell cycle and global transcription, providing a rationale for its therapeutic targeting in CRPC.
Methods:
The antitumour activity of CT7001, an orally bioavailable CDK7 inhibitor, was investigated across CRPC models in vitro and in xenograft models in vivo. Cell-based assays and transcriptomic analyses of treated xenografts were employed to investigate the mechanisms driving CT7001 activity, alone and in combination with the antiandrogen enzalutamide.
Results:
CT7001 selectively engages with CDK7 in prostate cancer cells, causing inhibition of proliferation and cell cycle arrest. Activation of p53, induction of apoptosis, and suppression of transcription mediated by full-length and constitutively active AR splice variants contribute to antitumour efficacy in vitro. Oral administration of CT7001 represses growth of CRPC xenografts and significantly augments growth inhibition achieved by enzalutamide. Transcriptome analyses of treated xenografts indicate cell cycle and AR inhibition as the mode of action of CT7001 in vivo.
Conclusions:
This study supports CDK7 inhibition as a strategy to target deregulated cell proliferation and demonstrates CT7001 is a promising CRPC therapeutic, alone or in combination with AR-targeting compounds.
Insights
Cyclin-dependent kinase 7 (CDK7) inhibition with CT7001 shows promise for treating castration-resistant prostate cancer (CRPC). CT7001 effectively reduces tumor growth and enhances the efficacy of standard therapies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Androgen receptor (AR) signaling is a key driver in prostate cancer, but current inhibitors are often overcome in castration-resistant prostate cancer (CRPC).
- Cyclin-dependent kinase 7 (CDK7) plays a critical role in promoting AR signaling, cell cycle progression, and global transcription, making it a potential therapeutic target in CRPC.
Purpose of the Study:
- To evaluate the anti-tumor activity and mechanism of action of CT7001, an orally bioavailable CDK7 inhibitor, in preclinical models of CRPC.
- To assess the efficacy of CT7001 as a monotherapy and in combination with enzalutamide, an anti-androgen therapy.
Main Methods:
- In vitro cell-based assays were used to assess proliferation, cell cycle arrest, apoptosis, and transcriptional changes in CRPC cells treated with CT7001.
- In vivo studies involved CRPC xenograft models treated with CT7001, alone and in combination with enzalutamide, with subsequent transcriptomic analysis of tumors.
Main Results:
- CT7001 selectively inhibited CDK7 in prostate cancer cells, leading to reduced proliferation, cell cycle arrest, p53 activation, and apoptosis.
- Transcriptomic analysis revealed suppression of AR-mediated transcription and cell cycle inhibition as key mechanisms of CT7001.
- In vivo, oral CT7001 significantly repressed CRPC xenograft growth and augmented the anti-tumor effect of enzalutamide.
Conclusions:
- CDK7 inhibition represents a viable strategy for targeting deregulated cell proliferation in CRPC.
- CT7001 demonstrates significant therapeutic potential as a standalone treatment or in combination with existing AR-targeting therapies for CRPC.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:39Positive Regulator Molecules